CDK4/6 Inhibition's Role in HR+ Metastatic Breast Cancer

See what leading breast oncologists have to say about practice-informing data to come out of the 2026 ESMO Congress.

Erica L. Mayer, MD, MPH, discusses the FDA approval of camizestrant for ESR1-mutated HR+/HER2– breast cancer and the importance of ctDNA monitoring.

Breast cancer experts answer key questions on selecting, sequencing, and managing ADCs in HR-positive, HER2-positive, and triple-negative disease.

A new clinical trial will investigate whether a simple blood test could help detect breast cancer as early as Stage I.

Phase 3 data showed a significant PFS improvement with trastuzumab pamirtecan vs chemotherapy in HR-positive, HER2-low metastatic breast cancer.